SEC Tracker
Get the app

Edgewise Therapeutics EWTX

Edgewise Therapeutics Q1 FY25: net loss $40.8M; diluted EPS −$0.43

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Key figures from this report

These are the numbers Edgewise Therapeutics reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$40.8MAgainst −$28.5M in Q1 FY2410-Q income statement, on EDGAR
  2. Diluted EPS−$0.43Against −$0.33 in Q1 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$49.9M+65% from $30.3M in Q1 FY2410-Q balance sheet, on EDGAR
  4. Cash from operations−$37.9MAgainst −$28.6M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Edgewise Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Innoviva INVA public float $1.3B, Jun 30, 2025
  2. Mannkind MNKD public float $1.1B, Jun 30, 2025
  3. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  4. Ani Pharmaceuticals ANIP public float $1.3B, Jun 30, 2025
  5. Celldex Therapeutics CLDX public float $1.3B, Jun 30, 2025